Company Profile

Amunix Inc (AKA: Amunix Operating Inc~Amunix Pharmaceuticals Inc)
Profile last edited on: 7/17/2023      CAGE: 4BU04      UEI: TE1JMXGDPZ47

Business Identifier: Harnessing immune system to tackle cancer
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2 Tower Place Unit 1100
South San Francisco, CA 94080
   (650) 428-1800
Location: Single
Congr. District: 18
County: San Mateo

Public Profile

In December 2021, it was announced that Amunix had been acquired by Sanofi for an amount indicated as $1B. Active in SBIR for some6-7 years after start-up, the firm had been structured around developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers. Leveraging the firm's proprietary T cell engager (XPAT™) and cytokine (XPAC) platforms the effort is to advance novel prodrugs that overcome the toxicity and immunogenicity challenges common to these therapeutic modalities via selective activation in the tumor microenvironment. By delivering breakthrough therapies that can safely harness the immune system, the effort is to conquer cancer and save lives. From the outsideof the firm's original establsihment in 2006, the approachhas been to operate as a technology licensing company. Management had previously forged agreements with various biopharmaceutical companies - Roche, Merck, Celgene, and Biogen - to leverage XTEN, a proprietary half-life extension technology, and Pro-XTEN, a next-generation prodrug technology. Pro-XTEN utilizes a protease-releasable XTEN polypeptide as a mask, thus enabling localized activation of potent therapies. This technology is designed to overcome a common challenge facing potent immune system activators: on-target, off-tumor toxicity. Pro-XTEN, which is the foundational technology for the XPAT and XPAC platforms, has been clinically validated, with the most advanced program utilizing the technology currently in a pivotal Phase 3 study for a non-oncology indication. The firm's lead development candidate currently is AMX-818 - an XPAT T cell engager targeting HER2+ solid tumors, toward the clinic

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Volker Schellenberger -- Co-Founder, President and CEO

  Angie You -- CEO

  Maninder Hora -- Chief Technical Operations Officer